- Home
- CRVS vs QURE Comparison
CRVS vs QURE Comparison
Compare CRVS & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRVS | QURE |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2016 | 2007 |
Fundamental Metrics
Financial Performance| Metric | CRVS | QURE |
|---|---|---|
| Price | $18.76 | $22.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $28.00 | ★ $56.25 |
| AVG Volume (30 Days) | ★ 7.7M | 1.8M |
| Earning Date | 03-24-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,751,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $142.93 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.54 | $7.76 |
| 52 Week High | $26.95 | $71.50 |
Technical Indicators
Market Signals| Indicator | CRVS | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 57.79 | 44.23 |
| Support Level | $18.50 | $24.37 |
| Resistance Level | $21.57 | $26.97 |
| Average True Range (ATR) | 1.69 | 2.07 |
| MACD | -0.59 | -0.04 |
| Stochastic Oscillator | 10.48 | 5.41 |
Price Performance
Historical ComparisonAbout CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.